316 related articles for article (PubMed ID: 28524746)
1. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
Salter A; Thomas NP; Tyry T; Cutter GR; Marrie RA
Mult Scler; 2018 Jun; 24(7):951-962. PubMed ID: 28524746
[TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
3. Profile of Polish patients with primary progressive multiple sclerosis.
Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
[TBL] [Abstract][Full Text] [Related]
4. Employment and absenteeism in working-age persons with multiple sclerosis.
Salter A; Thomas N; Tyry T; Cutter G; Marrie RA
J Med Econ; 2017 May; 20(5):493-502. PubMed ID: 28035846
[TBL] [Abstract][Full Text] [Related]
5. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
6. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
[TBL] [Abstract][Full Text] [Related]
7. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.
Castelo-Branco A; Landfeldt E; Svedbom A; Löfroth E; Kavaliunas A; Hillert J
Eur J Neurol; 2019 Apr; 26(4):603-609. PubMed ID: 30414299
[TBL] [Abstract][Full Text] [Related]
8. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
[TBL] [Abstract][Full Text] [Related]
9. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.
Hadjimichael O; Vollmer T; Oleen-Burkey M;
Health Qual Life Outcomes; 2008 Nov; 6():100. PubMed ID: 19014588
[TBL] [Abstract][Full Text] [Related]
10. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.
Tutuncu M; Tang J; Zeid NA; Kale N; Crusan DJ; Atkinson EJ; Siva A; Pittock SJ; Pirko I; Keegan BM; Lucchinetti CF; Noseworthy JH; Rodriguez M; Weinshenker BG; Kantarci OH
Mult Scler; 2013 Feb; 19(2):188-98. PubMed ID: 22736750
[TBL] [Abstract][Full Text] [Related]
11. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
[No Abstract] [Full Text] [Related]
12. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
13. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
[TBL] [Abstract][Full Text] [Related]
14. Natural history of primary progressive multiple sclerosis.
Ebers GC
Mult Scler; 2004 Jun; 10 Suppl 1():S8-13; discussion S13-5. PubMed ID: 15218804
[TBL] [Abstract][Full Text] [Related]
15. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis.
Planche V; Gibelin M; Cregut D; Pereira B; Clavelou P
Eur J Neurol; 2016 Feb; 23(2):282-9. PubMed ID: 25903918
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
17. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome.
Kantarci OH; Lebrun C; Siva A; Keegan MB; Azevedo CJ; Inglese M; Tintoré M; Newton BD; Durand-Dubief F; Amato MP; De Stefano N; Sormani MP; Pelletier D; Okuda DT
Ann Neurol; 2016 Feb; 79(2):288-94. PubMed ID: 26599831
[TBL] [Abstract][Full Text] [Related]
18. Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?
Schwartz CE; Quaranto BR; Healy BC; Benedict RH; Vollmer TL
Arch Phys Med Rehabil; 2013 Oct; 94(10):1971-81. PubMed ID: 23727344
[TBL] [Abstract][Full Text] [Related]
19. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
[TBL] [Abstract][Full Text] [Related]
20. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T
Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]